Literature DB >> 30776170

A novel approach to offering additional genomic findings-A protocol to test a two-step approach in the healthcare system.

Melissa Martyn1,2,3, Anaita Kanga-Parabia1,2,3, Elly Lynch1,3,4, Paul A James5,6, Ivan Macciocca3,4, Alison H Trainer5,6, Jane Halliday2,3, Louise Keogh2, Janney Wale1, Ingrid Winship6, Michael Bogwitz6, Giulia Valente7, Maie Walsh5,6, Lilian Downie2,3,4, David Amor2,8, Mathew Wallis7, Fiona Cunningham3,9, Matthew Burgess7, Natasha J Brown2,3,4,7,8, Anna Jarmolowicz3,4, Sebastian Lunke3,4, Ilias Goranitis2,3, Clara L Gaff1,2,3.   

Abstract

Internationally, the practice of offering additional findings (AFs) when undertaking a clinically indicated genomic test differs. In the USA, the recommendation is to include analysis for AFs alongside diagnostic analysis, unless a patient opts-out, whereas European and Canadian guidelines recommend opt-in models. These guidelines all consider the offer of AFs as an activity concurrent with the offer of diagnostic testing. This paper describes a novel two-step model for managing AFs within the healthcare system in Victoria, Australia and presents the study protocol for its evaluation. Adults who have received results of diagnostic whole exome sequencing undertaken within the healthcare system are invited to attend a genetic counseling appointment to consider reanalysis of their stored genomic data for AFs. The evaluation protocol addresses uptake, decision-making, understanding, counseling challenges, and explores preferences for future models of care. Recruitment commenced in November 2017 and will cease when 200 participants have been approached. When the study is concluded, the evaluation results will contribute to the evidence base guiding approaches to counseling and models of care for AFs.
© 2019 National Society of Genetic Counselors.

Entities:  

Keywords:  additional findings; decision-making; evaluation; genomics; reanalysis; secondary findings; service delivery

Mesh:

Year:  2019        PMID: 30776170     DOI: 10.1002/jgc4.1102

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  5 in total

1.  My Research Results: a program to facilitate return of clinically actionable genomic research findings.

Authors:  Amanda M Willis; Bronwyn Terrill; Angela Pearce; Alison McEwen; Mandy L Ballinger; Mary-Anne Young
Journal:  Eur J Hum Genet       Date:  2021-10-04       Impact factor: 4.246

2.  Making community voices heard in a research-health service alliance, the evolving role of the Community Advisory Group: a case study from the members' perspective.

Authors:  Janet L Wale; Louisa Di Pietro; Heather Renton; Margaret Sahhar; Christine Walker; Pamela Williams; Karen Meehan; Elly Lynch; Melissa Martyn; Jane Bell; Ingrid Winship; Clara L Gaff
Journal:  Res Involv Engagem       Date:  2021-11-27

Review 3.  A framework for reporting secondary and incidental findings in prenatal sequencing: When and for whom?

Authors:  Danya Vears; David J Amor
Journal:  Prenat Diagn       Date:  2022-01-19       Impact factor: 3.242

4.  Opportunistic genomic screening. Recommendations of the European Society of Human Genetics.

Authors:  Guido de Wert; Wybo Dondorp; Angus Clarke; Elisabeth M C Dequeker; Christophe Cordier; Zandra Deans; Carla G van El; Florence Fellmann; Ros Hastings; Sabine Hentze; Heidi Howard; Milan Macek; Alvaro Mendes; Chris Patch; Emmanuelle Rial-Sebbag; Vigdis Stefansdottir; Martina C Cornel; Francesca Forzano
Journal:  Eur J Hum Genet       Date:  2020-11-22       Impact factor: 4.246

5.  Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting.

Authors:  Megan C Best; Phyllis Butow; Jacqueline Savard; Chris Jacobs; Nicole Bartley; Grace Davies; Christine E Napier; Mandy L Ballinger; David M Thomas; Barbara Biesecker; Katherine M Tucker; Ilona Juraskova; Bettina Meiser; Timothy Schlub; Ainsley J Newson
Journal:  Eur J Hum Genet       Date:  2022-03-11       Impact factor: 5.351

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.